As of 10:46 on March 28, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose 1.63%, the constituent stocks Zai Lab (09688) rose 12.61%, Ascentage Pharma-B (06855) rose 7.49%, 3SBio (01530) rose 5.67%, Akeso Biopharma (09926), InnoCare (09969) and other stocks followed suit. Hong Kong Pharmaceutical ETF (159718) rose 1.25%, hitting three consecutive gains. The latest price is 0.73 yuan, and the intraday turnover has reached 83.5092 million yuan, with a turnover rate of 40.83%, and the market is actively trading.

As of 10:45 on March 28, 2025, the CSI Pharmaceutical and Medical Device Innovation Index (931484) rose 0.70%, the constituent stocks Baili Tianheng (688506) rose 9.60%, Shenzhou Cell (688520) rose 5.56%, Yirui Technology (688301) rose 4.94%, Jiudian Pharmaceutical (300705) rose 3.87%, and Haisco (002653) rose 3.74%. Medical Innovation ETF (516820) rose more than 1% in early trading, and is now up 0.86%, the latest price is 0.35 yuan, and the intraday turnover has reached 33.3803 million yuan, with a turnover rate of 1.88%.

In the long run, as of March 27, 2025, Hong Kong stock pharmaceutical ETFs have risen by 7.96% in the past two weeks, ranking 1/4 of comparable funds. Medical Innovation ETF has risen 3.26% in the last 2 weeks.

In terms of scale, the latest scale of medical innovation ETF reached 1.759 billion yuan.

The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of medical innovation ETF reached 14.6462 million yuan, and the latest financing balance reached 79.1504 million yuan.

On March 27, the report on the high-quality development achievements of innovative medical devices was held in Changping District, Beijing. At the report meeting, the "Medical Device Innovation Beijing Service Station of the Medical Device Technology Evaluation Center of the State Drug Administration" landed in Changping, and at the same time, Changping District announced the establishment of the "China High-end Medical Equipment Innovation and High-quality Development Exchange Center", and the "one station and one center" will be dual-core driven to empower the development of regional industries.

China Post Securities sorted out the performance of the innovative drug sector in 2024 and concluded that the overall performance of the sector showed a high growth trend. From the perspective of revenue, the overall growth trend is obvious, with 8 companies achieving a growth rate of more than 30%, of which Baili Tianheng has achieved a high growth rate of 936.3%. From the profit side, several innovative pharmaceutical companies will turn around their losses in 2024, including Shenzhou Cell, Baili Tianheng, Sinovac Pharmaceutical, etc., and Remegen, BeiGene, InnoCare, Alphamab Oncology, Zai Lab, Junshi Biosciences, etc., all achieved narrowing losses. We believe that driven by multiple policies, technologies, and aging, innovative pharmaceutical companies have entered a period of intensive commercialization.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of February 28, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are BeiGene (06160), WuXi Biologics (02269), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), CSPC Pharmaceutical Group (01093), Sino Biopharma (01177), Ali Health (00241), Zai Lab (09688), Sinopharm ( 01099), the top 10 weighted stocks accounted for 59.55% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of February 28, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Mindray Medical (300760), Hengrui Pharmaceutical (600276), Aier Ophthalmology (300015), United Imaging Healthcare (688271), Kelun Pharmaceutical (002422), Changchun High-tech (000661), Huadong Medicine (000963), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks together accounted for 66.9%.